GlassScriptPhysician profile
Chanda Danielle Harris
NPI 1942827787
$5,876.32
in general payments reported to CMS, 2019-2025
20 companies · $714 in 2025
The $714 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,348 · 2022: $1,433 · 2023: $1,006 · 2024: $1,376 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $909.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $826.99 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $826.87 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $654.28 | 2023-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $563.35 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $485.84 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $271.29 | 2021 | |
| Amarin Pharma, INC. | $219.20 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.10 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.34 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $158.21 | 2022 | |
| Ardelyx, INC. | $146.94 | 2025 | Ibsrela |
| Averitas Pharma INC. | $121.59 | 2023 | Qutenza |
| Horizon Therapeutics Plc | $95.06 | 2021-2022 | |
| Exact Sciences Corporation | $91.24 | 2023-2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.37 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $44.39 | 2021 | |
| Dexcom, INC. | $22.17 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $20.81 | 2021 | |
| Currax Pharmaceuticals LLC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanda Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.